NS309

A potent activator of Ca2+ -activated K+ channels of SK and IK types but not BK type channels. NS309 is at least 1000 times more potent than 1-EBIO and at least 30 times more potent than DC-EBIO when the compounds are compared on the same cell. NS309 blocks L-type Calcium channels with IC₅₀ = 10 µM/L. Recently, this compound has been shown to produce endothelium-dependent hyperpolarizations in guinea pig carodid arteries by opening KCa2.3 and KCa3.1 channels demonstrating a new therapeutic option for treating hypertension.

A potent activator of Ca2+ -activated K+ channels of SK and IK types but not BK type channels. NS309 is at least 1000 times more potent than 1-EBIO and at least 30 times more potent than DC-EBIO when the compounds are compared on the same cell. NS309 blocks L-type Calcium channels with IC₅₀ = 10 µM/L. Recently, this compound has been shown to produce endothelium-dependent hyperpolarizations in guinea pig carodid arteries by opening KCa2.3 and KCa3.1 channels demonstrating a new therapeutic option for treating hypertension.

Please note that the molecular weight for this compound is batch-specific due to variable water content.

Primary Target
Ca2+-activated K+ channels

Toxicity: Standard Handling (A)

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.

Leurangue, V. et al. 2008. Naunyn Schmiedebergs Arch. Pharmacol.377, 101.
Morimura, K. et al. 2006. J. Pharmacol. Sci.100, 237.
Strobaek, D. et al. 2004. Biochim. Biophys. Acta.1665, 1.

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany